Furthermore, a more detailed study of the tumor-ECM interaction involving tumor-associated remodeling markers and ECM factors, such as CD10-FGF2 interaction, could show promise as an immunological profile of aggressive and invasive tumors and distinguish them from more indolent forms. This evidence concerns the gene FGF2 and neoplasm.